Drug name - Igalmi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792246 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 5, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 0.12MG BASE FILM;BUCCAL, SUBLINGUAL Prescription
EQ 0.18MG BASE FILM;BUCCAL, SUBLINGUAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.